Literature DB >> 3300347

Prescription drug use before and during pregnancy in a Medicaid population.

J M Piper, C Baum, D L Kennedy.   

Abstract

This study describes prescription drug use before and during pregnancy and is based on data obtained from the paid Medicaid claims of 18,886 Michigan women aged 15 to 44 years who were delivered of a live infant. Rates of exposure to drugs within 15 therapeutic categories are presented for each of five 90-day periods preceding delivery. Overall dispensed drug use (excluding vitamins) decreased during pregnancy; however, there was still substantial exposure to drugs including drugs that are contraindicated during pregnancy. During the gestational period, study mothers received an average of 3.1 prescriptions for nonvitamin drugs. Black mothers received more exposure to drugs other than vitamins than did white mothers. Black mothers had higher rates of exposure to analgesics, ampicillin, codeine, and vaginal preparations. Similarities between black and white mothers in the use of vitamins with and without other drugs suggest there is no racial difference in attaining prenatal care within the Medicaid system, but that black mothers may have more medical problems that warrant the use of other medications in addition to vitamins during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300347     DOI: 10.1016/s0002-9378(87)80368-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Investigating drug use in pregnancy. Methodological problems and perspectives.

Authors:  L T De Jong-van den Berg; P B Van den Berg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

2.  Drug use in pregnancy: an overview of epidemiological (drug utilization) studies.

Authors:  M Bonati; R Bortolus; F Marchetti; M Romero; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

4.  Information on drug use in pregnancy from the Viewpoint Regional Drug Information Centre.

Authors:  O Kasilo; M Romero; M Bonati; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Drug use in pregnancy: a comparative appraisal of data collecting methods.

Authors:  L T de Jong-van den Berg; C M Waardenburg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.

Authors:  Margaret A Honein; Cynthia A Moore; J David Erickson
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Handling of risk-bearing drugs during pregnancy. Do we choose less risky alternatives?

Authors:  L T De Jong-Van den Berg; P B Van den Berg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling
Journal:  Pharm Weekbl Sci       Date:  1992-04-24

8.  Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy.

Authors:  Joshua J Gagne; Vittorio Maio; Vincenzo Berghella; Daniel Z Louis; Joseph S Gonnella
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

9.  Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon M Dyer; Patricia S Gideon; Kathleen S Hall; Lisa A Kaltenbach; Wayne A Ray
Journal:  Paediatr Perinat Epidemiol       Date:  2009-01       Impact factor: 3.980

Review 10.  Safe prescribing practices in pregnancy and lactation.

Authors:  Wendy F Hansen; Anne E Peacock; Jerome Yankowitz
Journal:  J Midwifery Womens Health       Date:  2002 Nov-Dec       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.